BAXTER INTL INC's ticker is BAX and the CUSIP is 071813109. A total of 1,001 filers reported holding BAXTER INTL INC in Q4 2022. The put-call ratio across all filers is 0.54 and the average weighting 0.1%.
About BAXTER INTL INC
Baxter International Inc. is a global healthcare company that specializes in developing and manufacturing medical products and therapies. The company has a long history of innovation and has been at the forefront of developing life-saving treatments for patients around the world.
Baxter's product portfolio includes a wide range of medical devices, pharmaceuticals, and biotechnology products. The company's products are used in hospitals, clinics, and other healthcare settings to treat a variety of conditions, including hemophilia, immune disorders, kidney disease, and other chronic and acute medical conditions.
Baxter's commitment to innovation has helped the company maintain a strong position in the healthcare industry. The company invests heavily in research and development, and has a strong pipeline of new products in development.
Baxter's leadership team is also a key strength of the company. The CEO, José Almeida, has a strong track record of success in the healthcare industry, and has been instrumental in driving the company's growth and success.
Overall, Baxter International Inc. is a strong and innovative company that is well-positioned to continue delivering value to patients, healthcare providers, and investors alike. With a strong product portfolio, a commitment to innovation, and a talented leadership team, Baxter is a company that investors should keep an eye on in the years to come.
It's important to note that this information is for educational purposes only and has not been fact-checked. As with any investment, it's important to do your own research and consult with a financial advisor before making any investment decisions.
Quarter-by-quarter ownership
Value | Shares | Weighting | ||||
---|---|---|---|---|---|---|
Q2 2024 | $37,497 | -81.1% | 1,121 | -75.8% | 0.00% | -78.9% |
Q1 2024 | $198,228 | +11.8% | 4,638 | +1.1% | 0.02% | +5.6% |
Q4 2023 | $177,295 | +11.5% | 4,586 | +8.8% | 0.02% | 0.0% |
Q3 2023 | $159,036 | -10.4% | 4,214 | +8.2% | 0.02% | -5.3% |
Q2 2023 | $177,502 | +15.2% | 3,896 | +2.6% | 0.02% | +5.6% |
Q1 2023 | $154,087 | +4.7% | 3,799 | +31.5% | 0.02% | 0.0% |
Q4 2022 | $147,201 | +5.1% | 2,888 | +11.0% | 0.02% | -25.0% |
Q3 2022 | $140,000 | -19.5% | 2,601 | -3.9% | 0.02% | -17.2% |
Q2 2022 | $174,000 | -15.5% | 2,706 | +1.7% | 0.03% | -9.4% |
Q1 2022 | $206,000 | -13.1% | 2,660 | -3.6% | 0.03% | -11.1% |
Q4 2021 | $237,000 | +383.7% | 2,758 | +349.2% | 0.04% | +176.9% |
Q3 2021 | $49,000 | -2.0% | 614 | -0.6% | 0.01% | +18.2% |
Q2 2021 | $50,000 | -5.7% | 618 | -1.1% | 0.01% | -8.3% |
Q1 2021 | $53,000 | -3.6% | 625 | -8.5% | 0.01% | -7.7% |
Q4 2020 | $55,000 | +3.8% | 683 | +2.9% | 0.01% | -13.3% |
Q3 2020 | $53,000 | -7.0% | 664 | -0.3% | 0.02% | -11.8% |
Q2 2020 | $57,000 | -12.3% | 666 | -17.1% | 0.02% | -32.0% |
Q1 2020 | $65,000 | -31.6% | 803 | -29.2% | 0.02% | -24.2% |
Q4 2019 | $95,000 | -5.0% | 1,134 | -1.0% | 0.03% | -13.2% |
Q3 2019 | $100,000 | +7.5% | 1,146 | +0.5% | 0.04% | +5.6% |
Q2 2019 | $93,000 | -6.1% | 1,140 | -7.2% | 0.04% | -7.7% |
Q1 2019 | $99,000 | +59.7% | 1,228 | +29.5% | 0.04% | +25.8% |
Q4 2018 | $62,000 | – | 948 | – | 0.03% | – |
Download |
Other shareholders
Name | Shares | Value | Weighting ↓ |
---|---|---|---|
Third Point | 36,000,000 | $2,658,240,000 | 18.52% |
SECTOR GAMMA AS | 721,058 | $53,243,000 | 8.85% |
SUVRETTA CAPITAL MANAGEMENT, LLC | 2,747,061 | $202,843,000 | 5.38% |
Veritas Asset Management LLP | 8,852,005 | $653,632,000 | 5.36% |
Knowledge Leaders Capital, LLC | 79,384 | $5,862,000 | 4.39% |
HealthCor Management, L.P. | 1,800,000 | $132,912,000 | 4.22% |
Progressive Investment Management Corp | 79,282 | $5,854,000 | 3.78% |
13D Management LLC | 200,318 | $14,791,000 | 3.77% |
ARGENT CAPITAL MANAGEMENT LLC | 1,288,236 | $95,123,000 | 3.42% |
Chiron Investment Management, LLC | 612,787 | $45,248,000 | 3.12% |